Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Biomarkers of risk to develop lung cancer in the new screening era.

Atwater T, Massion PP.

Ann Transl Med. 2016 Apr;4(8):158. doi: 10.21037/atm.2016.03.46. Review.

2.

Personalized Cancer Risk Assessments for Space Radiation Exposures.

Locke PA, Weil MM.

Front Oncol. 2016 Feb 22;6:38. doi: 10.3389/fonc.2016.00038. eCollection 2016. Review.

3.

Soluble Human Epidermal Growth Factor Receptor 2 (sHER2) as a Potential Risk Assessment, Screening, and Diagnostic Biomarker of Lung Adenocarcinoma.

Cosentino-Boehm AL, Lafky JM, Greenwood TM, Kimbler KD, Buenafe MC, Wang Y, Branscum AJ, Yang P, Maihle NJ, Baron AT.

Diagnostics (Basel). 2013 Jan 14;3(1):13-32. doi: 10.3390/diagnostics3010013.

4.

Lung cancer risk test trial: study design, participant baseline characteristics, bronchoscopy safety, and establishment of a biospecimen repository.

Crawford EL, Levin A, Safi F, Lu M, Baugh A, Zhang X, Yeo J, Khuder SA, Boulos AM, Nana-Sinkam P, Massion PP, Arenberg DA, Midthun D, Mazzone PJ, Nathan SD, Wainz R, Silvestri G, Tita J, Willey JC.

BMC Pulm Med. 2016 Jan 22;16:16. doi: 10.1186/s12890-016-0178-4.

5.

Review of carcinogenicity of asbestos and proposal of approval standards of an occupational cancer caused by asbestos in Korea.

Im S, Youn KW, Shin D, Lee MJ, Choi SJ.

Ann Occup Environ Med. 2015 Dec 30;27:34. doi: 10.1186/s40557-015-0080-1. eCollection 2015.

6.

China national lung cancer screening guideline with low-dose computed tomography (2015 version).

Zhou QH, Fan YG, Bu H, Wang Y, Wu N, Huang YC, Wang G, Wang XY, Qiao YL.

Thorac Cancer. 2015 Nov;6(6):812-8. doi: 10.1111/1759-7714.12287. Epub 2015 Aug 4.

7.

An official American Thoracic Society/American College of Chest Physicians policy statement: implementation of low-dose computed tomography lung cancer screening programs in clinical practice.

Wiener RS, Gould MK, Arenberg DA, Au DH, Fennig K, Lamb CR, Mazzone PJ, Midthun DE, Napoli M, Ost DE, Powell CA, Rivera MP, Slatore CG, Tanner NT, Vachani A, Wisnivesky JP, Yoon SH; ATS/ACCP Committee on Low-Dose CT Lung Cancer Screening in Clinical Practice.

Am J Respir Crit Care Med. 2015 Oct 1;192(7):881-91. doi: 10.1164/rccm.201508-1671ST.

PMID:
26426785
8.

Mouse double minute-2 homolog (MDM2)-rs2279744 polymorphism associated with lung cancer risk in a Northeastern Chinese population.

Wang X, Jin L, Cui J, Ma K, Chen X, Li W.

Thorac Cancer. 2015 Jan;6(1):91-6. doi: 10.1111/1759-7714.12153. Epub 2015 Jan 7.

9.

Screening for lung cancer using low-dose computed tomography: concerns about the application in low-risk individuals.

Cui JW, Li W, Han FJ, Liu YD.

Transl Lung Cancer Res. 2015 Jun;4(3):275-86. doi: 10.3978/j.issn.2218-6751.2015.02.05. Review.

10.

Using Clinical Risk Models for Lung Nodule Classification.

Deppen SA, Grogan EL.

Semin Thorac Cardiovasc Surg. 2015 Spring;27(1):30-5. doi: 10.1053/j.semtcvs.2015.04.001. Epub 2015 Apr 7. Review.

11.

A simple model for predicting lung cancer occurrence in a lung cancer screening program: The Pittsburgh Predictor.

Wilson DO, Weissfeld J.

Lung Cancer. 2015 Jul;89(1):31-7. doi: 10.1016/j.lungcan.2015.03.021. Epub 2015 Mar 28.

PMID:
25863905
12.

RNA-sequencing studies identify genes differentially regulated during inflammation-driven lung tumorigenesis and targeted by chemopreventive agents.

Qian X, Khammanivong A, Song JM, Teferi F, Upadhyaya P, Dickerson E, Kassie F.

Inflamm Res. 2015 May;64(5):343-61. doi: 10.1007/s00011-015-0815-z. Epub 2015 Mar 21.

13.

Machine learning applications in cancer prognosis and prediction.

Kourou K, Exarchos TP, Exarchos KP, Karamouzis MV, Fotiadis DI.

Comput Struct Biotechnol J. 2014 Nov 15;13:8-17. doi: 10.1016/j.csbj.2014.11.005. eCollection 2015. Review.

14.

JNCI and cancer prevention.

Dunn BK, Ghosh S, Kramer BS.

J Natl Cancer Inst. 2015 Feb 24;107(3). pii: djv021. doi: 10.1093/jnci/djv021. Print 2015 Mar.

15.

Development and validation of a personalized, web-based decision aid for lung cancer screening using mixed methods: a study protocol.

Lau YK, Caverly TJ, Cherng ST, Cao P, West M, Arenberg D, Meza R.

JMIR Res Protoc. 2014 Dec 19;3(4):e78. doi: 10.2196/resprot.4039.

16.

Targeting the estrogen pathway for the treatment and prevention of lung cancer.

Burns TF, Stabile LP.

Lung Cancer Manag. 2014 Feb 1;3(1):43-52.

17.

Components necessary for high-quality lung cancer screening: American College of Chest Physicians and American Thoracic Society Policy Statement.

Mazzone P, Powell CA, Arenberg D, Bach P, Detterbeck F, Gould MK, Jaklitsch MT, Jett J, Naidich D, Vachani A, Wiener RS, Silvestri G.

Chest. 2015 Feb;147(2):295-303. doi: 10.1378/chest.14-2500.

18.

What characteristics of primary care and patients are associated with early death in patients with lung cancer in the UK?

O'Dowd EL, McKeever TM, Baldwin DR, Anwar S, Powell HA, Gibson JE, Iyen-Omofoman B, Hubbard RB.

Thorax. 2015 Feb;70(2):161-8. doi: 10.1136/thoraxjnl-2014-205692. Epub 2014 Oct 13.

19.

A review of cancer risk prediction models with genetic variants.

Wang X, Oldani MJ, Zhao X, Huang X, Qian D.

Cancer Inform. 2014 Sep 21;13(Suppl 2):19-28. doi: 10.4137/CIN.S13788. eCollection 2014. Review.

20.

The cytokinesis-blocked micronucleus assay as a strong predictor of lung cancer: extension of a lung cancer risk prediction model.

El-Zein RA, Lopez MS, D'Amelio AM Jr, Liu M, Munden RF, Christiani D, Su L, Tejera-Alveraz P, Zhai R, Spitz MR, Etzel CJ.

Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2462-70. doi: 10.1158/1055-9965.EPI-14-0462. Epub 2014 Aug 29.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk